[Telithromycin].
For the time being telithromycin is the only representative of a new group of antibiotics - ketolides - available for clinical use. Its chemical structure is derived from erythromycin, but it is better resorbed from the digestive tract and is efficacious against most macrolide-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes. Telithromycin is registered for the treatment of respiratory infections: sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia and streptococcal tonsillopharyngitis. The drug is well tolerated. It is less likely to induce MLS(B) resistance than macrolides with a 14- or 15-member ring.
Benes
Jirí
J
Dept. Infect. Dis., 3rd Med. Faculty, Charles University, 18081 Prague 8, Czech Republic. benesj@cesnet.cz
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D004351:Drug Resistance; D006801:Humans; D048628:Ketolides; D018942:Macrolides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin